2022 NATIONAL INTEGRATED CONTENT FEATURE

NEWSPAPER

AND DIGITAL

Neuroendocrine Tumour (NET) Cancer Day



PUBLICATION DATE: Thursday, November 10 GET INVOLVED BY: Thursday, September 29 PRINT/DIGITAL AD MATERIAL DUE: Thursday, November 3 INVESTMENT: SPECIAL NATIONAL FEATURE/CONTRACT RATES APPLY

As the fastest growing cancer class worldwide, neuroendocrine tumours affect an increasing number of Canadians. This special feature, published to coincide with World NET Cancer Day, will raise awareness about the impact of this group of malignant growths and highlight efforts to push for scientific advancements as well as create a network of support for neuroendocrine tumour patients and the medical community dedicated to their care.

Proposed topic highlights:

ADVOCACY & RESOURCES – Profiling advocates, initiatives and support systems dedicated to helping neuroendocrine tumour patients.

RESEARCH – Advances in understanding about risk factors, diagnosis and treatment options promising hope.

OUTLOOK – From building awareness to boosting outcomes within the Canadian health-care system.

Sponsor content is available. Speak to your account manager for more information.

GET INVOLVED TODAY. CONTACT: RICHARD DEACON, Project Manager T: 1.604.631.6636 E: rdeacon@globeandmail.com

INTEGRATED CONTENT FEATURES

ARE TURNKEY ADVERTORIAL SOLUTIONS. PARTICIPATING ADVERTISERS CAN BE MENTIONED/QUOTED WITHIN CONTENT SPACE.

THE GLOBE AND MAIL DELIVERS YOUR BEST AUDIENCE

PRINT/DIGITAL: National Edition 6,367,000 WEEKLY PRINT/DIGITAL READERS Source: Vividata Fall 2021, National A14+

PRINT: National Edition 714,000 WEEKDAY PRINT READERS

Source: Vividata Fall 2021, National, A14+

Click on the report below to see a similar feature

World Neuroendocrine Tumour (NET)



THE GLOBE AND MAIL Media Group